Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
MAGNEVIST is a gadolinium-based contrast agent administered by injection, used across multiple therapeutic areas including cardiovascular imaging, oncology, and CNS disorders. The product functions as a diagnostic imaging enhancer for MRI procedures, enabling visualization of tissue perfusion and vascular abnormalities. It is indicated for peripheral vascular disease, renal pathology, brain tumors, breast cancer detection, myocardial infarction assessment, and fibrosis evaluation.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team focus likely shifting toward lifecycle extension, value defense, or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Gadobutrol Magnevist-controlled Body Study
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Magnevist Post-marketing Surveillance in Japan
Multihance Versus Magnevist in Breast MRI
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Worked on MAGNEVIST at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MAGNEVIST offers limited near-term career growth due to LOE approaching status and zero linked job postings; opportunities are concentrated in defensive commercial roles focused on market protection and payer negotiations. Professionals joining this team should expect stability in core functions but reduced expansion headcount and increased focus on operational efficiency during the transition to generic competition.